For the latest press releases, please visit our investors page.
As blood-based biomarkers continue to reshape the landscape of Alzheimer disease (AD) diagnosis and research, advances in highly sensitive detection technologies are enabling researchers to investigate a broader range of
A commercial assay that measures eMTBR-tau may be an alternative to tau PET imaging in diagnosing Alzheimer’s disease, according to data presented at the Alzheimer’s Association International Conference. Definitive diagnoses
NEW YORK – A group of researchers working as part of the National Institute of Aging-funded Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) is using Alamar Biosciences’ NULISAseq
National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer’s Disease and Related Dementias (ADRD) participants using Alamar Biosciences’ NULISAseq™ Neuro 220 panel. Resulting dataset will be publicly accessible, linked
Topic/Product: Dried blood spot sampling offers a practical route to biological sample collection outside the clinic. A few drops of blood can dry on a collection device, ship at ambient
Topic/Product: At the annual AD/PD conference, held March 17 to 21 in Copenhagen, Gustav Ceder interviewed Henrik Zetterberg about what is top of mind in neurodegenerative disease research right now. Zetterberg
Topic/Product: On a recent press trip to Oxford, Gustav Ceder visited John Todd, PhD, at the Centre for Human Genetics to discuss his latest research and reflect on the path
Topic/Product: Abstract Henrik Zetterberg is Professor of Neurochemistry at University College London (UCL) and at the University of Gothenburg, and a Senior Consultant in Clinical Chemistry at Sahlgrenska University Hospital. His
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.